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Accumulating evidence suggests autophagy, the principle catabolic process for 
lysosomal degradation of surplus macromolecules (Roy and Debnath 2010) is 
fundamental to tumourigenesis. Impaired autophagy results in accumulation of 
cellular breakdown products, increased oxidative stress and neoplastic 
transformation (Mathew et al. 2009); whilst efficient autophagy facilitates metastatic 
tumour survival through sustained metabolic activity (Roy and Debnath 2010). 
Consequently, the currently accepted view is that autophagy suppresses growth 
early in tumour development but promotes tumour survival at later stages (Garber 
2011).  
p62 (also known as sequestosome-1/SQSTM1) is a multidomain adaptor protein 
transporting ubiquitinated proteins during autophagy (Moscat and Diaz-Meco 2009); 
as such, p62 plays a role in selective autophagic degradation of a number of 
substrates (Komatsu and Ichimura 2010; Ichimura and Komatsu 2010). Normally, 
p62 is broken down along with its cargo within the autophagolysosome. However, 
impaired autophagy is accompanied by p62 accumulation, resulting in large 
p62/ubiquitinated protein aggregates (Komatsu and Ichimura 2010); a process 
thought to be a key factor in tumourigenesis (Moscat and Diaz-Meco 2009).  
The present biomarker discovery study aimed to define immunohistochemical p62 
expression as a prognostic biomarker in a retrospective cohort comprising 29 
melanocytic naevi and 121 primary cutaneous melanomas (Supplementary Methods 
and Table S1). In keeping with the “autophagy paradox”, we hypothesised p62 levels 
would be elevated in melanoma compared to naevi, with the highest levels detected 
in early stage disease where conditions represent a pro-tumourgenic environment.   
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Comparison of median p62 expression levels between naevi and all melanomas 
revealed a significant increase in expression levels in melanoma (14.82%) compared 
to naevi (0.51%; Mann-Whitney U, P <0.0001) (Fig 1a), and a step-wise increase in 
median p62 expression levels with localised tumour development (0.51% in naevi to 
44.5% in AJCC II disease, Mann-Whitney P < 0.0001) (Fig 1b). A relative decrease 
in median p62 expression (to 10.25%) was then observed in primary tumours from 
patients with metastatic stage III/IV disease (Stage II vs Stage III/IV Mann-Whitney P 
= 0.005) (Fig 1b). This biphasic expression in primary melanomas thus mirrors the 
“autophagy paradox”. 
To determine the efficacy of p62 expression levels at identifying high risk tumours at 
diagnosis, comparison of localised and metastatic disease (eventual AJCC stages 
I/II versus stages III/IV) revealed significantly lower median p62 expression in the 
metastatic cohort (10.25% versus 26.94% in AJCC I/II; Mann-Whitney, P = 0.016). 
p62 levels were visibly bimodal, with a Wilcoxon signed-rank test confirming that 
20% expression was an appropriate cut-point for undertaking survival curve analysis, 
and as such statistical modelling was based on tumour p62 expression above (“high 
p62”) or below 20% (“low p62”). 
Univariate analysis in all tumours was used to assess disease outcome over a 7-
year follow up period and revealed a modest, yet statistically significant, reduction in 
disease free survival (DFS) in patients with “low p62” tumours (40.9% of patients in 
the “low p62” group developed metastases compared to 21.8% in “high p62” tumours 
(Log-Rank (Mantel-Cox) Test P = 0.03, HR 1.66 (95% CI 1.03 – 2.69) (Fig 2a).  
Comparable univariate analysis of melanoma specific mortality (MSM) in the whole 
melanoma cohort revealed a non-significant trend towards an increased MSM in 
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patients with “low p62” tumours (MSM 24.24% “low p62” tumours, versus 14.55% in 
“high p62” tumours (Log-Rank (Mantel-Cox) Test P = 0.18, HR 1.5 (95% CI 0.83 – 
2.74). Univariate analysis of other pre-hypothesised risk factors for disease 
progression were calculated (Supplementary Methods and Table S2); as expected 
there was a significant increased risk of metastases with increasing Breslow depth 
and tumour ulceration in line with AJCC staging criteria (Balch et al. 2009). 
Univariate analysis of tumours pre-stratified to AJCC stage II at diagnosis revealed 
low p62 expression levels were associated with a trend for worse DFS; with 67.74% 
of patients in the “low p62” cohort developing a metastasis within 7-years compared 
to only 39.13% in the “high p62” group (Log-Rank (Mantel-Cox) Test) P = 0.06, HR 
1.7 (95% CI 0.97 – 2.96) (Fig 2b).  A similar trend was seen in AJCC stage I disease, 
(Log-Rank (Mantel-Cox) Test P = 0.38, HR 1.53 (95% CI 0.58 – 4.09).  
MSM followed an identical trend, with “low p62” AJCC stage II tumours resulting in a 
higher mortality rate compared to “high p62” AJCC II tumours (MSM 35.48% versus 
21.74% respectively (Log-Rank (Mantel-Cox) Test P = 0.27, HR 1.51 (95% CI 0.72 – 
3.2). 
Comparison of mean p62 expression revealed no association with Breslow depth or 
tumour ulceration (Figure S1) and Cox proportional hazards analysis undertaken to 
assess whether the predictive effects of p62 may be partially attributable to 
covariates (Supplementary Methods and Table S3) further supported p62 expression 
levels as an independent stratifying prognostic variable (p < 9E-7), representing 
biologically distinct processes to those included in AJCC staging alone. 
As a marker of autophagic activity, the p62 status of the current melanoma cohort fits 
with the “autophagy paradox”; with the highest levels of p62 expression found in 
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early, localised disease (AJCC stages I and II) in keeping with pro-tumourigenic 
dysfunctional autophagy. However, tumour cells with increased levels of autophagic 
activity (either through reactivation or retention of this function following 
tumourigenesis) are more likely to metastasise by harnessing pro-survival 
autophagy. 
Independently of its role in autophagy, p62 expression may be regulated by other 
signalling mechanisms including via NF-B activation and interaction with TRAF6 
and caspase-8 (Mathew et al. 2009; Komatsu and Ichimura 2010). Therefore, the 
differential expression of p62 within different AJCC stages of melanoma cannot be 
assumed to result entirely from impaired autophagic activity. Nevertheless, results 
from the present study add to the growing body of evidence supporting the 
introduction of autophagy inhibitors to chemotherapeutic regimes in melanoma, 
stage I trials of which are currently underway (Komatsu et al 2007), for which p62 
expression will likely provide a useful stratification criterion. Crucially however, p62 
represents a potential candidate biomarker that may provide additional prognostic 
information to AJCC disease stage. Further validation in an independent 
retrospective and ongoing prospective cohort will determine the prognostic 
significance and effect size of p62 and its application as a biomarker for refining 
personalised therapies, ultimately translating into improved clinical outcome for 
melanoma patients. 
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Figure legends 
Figure 1: p62 expression in melanoma is consistent with the ‘autophagy 
paradox’ in cancer 
(a) Median p62 expression levels were significantly higher in melanoma compared to 
benign melanocytic naevi (Mann-Whitney U, P <0.0001). Horizontal lines represent 
median expression levels. (b) Median p62 expression levels increased between 
benign naevi and localised melanoma (eventual AJCC stages I and II), but revealed 
a relative fall in metastatic disease (eventual AJCC stages III and IV) (Kruskal-Wallis 
P <0.0001). Horizontal lines represent median expression levels. 
Figure 2: p62 as a potential prognostic biomarker in melanoma  
(a) Univariate analysis of p62 expression revealed a significantly increased risk of 
metastasis in tumours expressing <20% p62 compared to tumours expressing >20% 
p62 (Log-Rank (Mantel-Cox) P = 0.03, HR 1.66 (95% CI 1.03 – 2.69). (b) Analysis of 
p62 expression levels after initial stratification by AJCC stage of disease reveals a 
suggestive increased risk of metastasis in AJCC stage II primary tumours with p62 
expression <20% compared to tumours expressing >20% p62 (Log-Rank (Mantel-
Cox) P = 0.06, HR 1.70 (95% CI 0.97 – 2.96). The number of patients remaining at 
risk at 20 month intervals is stated below the x-axis. 
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SUPPLEMENTARY MATERIALS AND METHODS 
1. Patients 
Retrospective formalin-fixed paraffin-embedded tissue was obtained from a cohort of 150 
samples comprising 29 benign melanocytic naevi and 121 primary melanomas of AJCC 
disease stages I or II at the time of diagnosis and excision at the Royal Victoria Infirmary, 
Newcastle-upon-Tyne between January 2003 and May 2005. Ethical permission for the 
study was obtained from the Newcastle and North Tyneside research ethics committee 
(REF; 08/H0906/95) with written, informed patient consent obtained as appropriate, and 
the study performed in accordance with the Declaration of Helsinki Principles. The sample 
cohort was selected based on pre-study power calculations following pilot data to provide 
a 95% power to detect a correlation (r) of ≥ 0.2 with p62 expression at the P ≤ 1E-05 level. 
These power calculations revealed 24 samples were required in each eventual AJCC 
disease subgroup (benign naevi, AJCC stage I, II and combined III/IV; 96 samples in 
total). Tumour subtypes were limited to primary cutaneous superficial spreading or 
nodular melanomas, with the exclusion of acral or lentigenous subtypes. Clinical staging 
was based on the 2009 AJCC clinical staging criteria. Data were correlated with clinical 
outcome after a minimum of seven years follow-up using case-note examination, allowing 
the correlation of p62 expression in the primary tissue sample with the time to 
development of first metastasis (disease free survival; DFS) or time to death from 
melanoma (melanoma specific mortality; MSM). Reporting of the data was performed in 
line with the REMARK guidelines for tumour marker prognostic studies (McShane et al, 
2005). 
McShane LM, Altman DG, Sauerbrei W, et al. (2005). Reporting Recommendations for Tumor Marker 
Prognostic Studies (REMARK). J Natl Canc Inst 97:1180-1184 
  
2. Immunohistochemistry 
Immunohistochemistry for p62 and MelanA expression were carried out as previously 
described (Hiscutt et al, 2010). p62 was detected with monoclonal anti-p62 (Santa Cruz 
Biotechnology Inc. USA; 1:50 with antigen retrieval performed using 0.1M Tris-HCl pH 
9), and Melan A with monoclonal anti-Melan A (Abcam, USA; 1:500; antigen retrieval 
with 0.1M Tris-HCl pH 7.6), both for 1 hour at room temperature and primary antibody 
binding detected with mouse IgG ABC Elite Vectastain Kit (Vector Laboratories Inc., 
Burlingame, USA) developed with Vector VIP (Vector Laboratories).  
 
3. Evaluation of NRAS and BRAF activating mutations in the patient cohort  
DNA was extracted from FFPE tissue blocks using QIAamp® DNA FFPE Tissue Kit 
(Qiagen, Crawley, UK) according to the manufacturer’s protocol. Immediate tissue 
sections to those taken for routine histology were taken for DNA extraction. PCR 
amplification and sequencing of the two most common NRAS codon-61 Single 
Nucleotide Polymorphisms (SNPs) on exon 2: NRAS Q61K and Q61R; as well as the 
SNPs for BRAF V600D and V600E mutations were performed using custom made 
primer and probes as previously described (Hiscutt et al, 2010). SNP analysis revealed 
the presence of 12 NRAS Q61R, 7 NRAS Q61K, 48 BRAF V600E mutations and 54 
samples wild-type for all tested mutations. No BRAF V600D mutations were found in the 
study population. 
 
Hiscutt EL, Hill DS, Martin S, et al. (2010). Targeting X-Linked Inhibitor of Apoptosis Protein to 
Increase the Efficacy of Endoplasmic Reticulum Stress-Induced Apoptosis for Melanoma Therapy. J 
Invest Dermatol 130:2250-2258 
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4. Immunohistochemical analysis and p62 quantification 
The mean percentage positively stained cells was derived by the analysis of up to ten 
representative 20x magnification microscope fields of vision and expressed as an 
overall mean percentage of cells expressing p62, using Leica QWin image analysis 
software (Leica Microsystems). IHC analysis was validated using FFPE cells of known 
p62 expression, and inter-assay variability assessed by repeated staining of positive 
and negative ‘control’ tumour samples which demonstrated a near identical staining 
pattern and reproducible percentage of cellular staining positivity. Tumour tissue was 
confirmed by the expression of Melan A in tissue from a matched serial section (Hiscutt 
et al, 2010) and microscopic analysis by the study pathologist. Although blinding for the 
diagnosis and major histological criteria was impossible without compromising selection 
of areas for photography, both assessors (study Dermatologist and Pathologist) were 
blinded to eventual disease outcome.    
5. Patient Demographics 
The 2009 AJCC staging criteria was used to define the clinical stage of disease of the 
150 patient cohort at diagnosis, revealing 29 benign melanocytic naevi, 67 AJCC stage 
I, and 54 AJCC stage II tumours. Patient outcome was determined after a minimum of 
seven years follow-up using case note examination. Disease recurrence was defined by 
the time to first radiological or tissue diagnosis of metastatic disease (nodal or systemic) 
from the point of initial primary tumour excision. Further patient demographic data is 
outlined in Table S1.     
 
Hiscutt EL, Hill DS, Martin S, et al. (2010). Targeting X-Linked Inhibitor of Apoptosis Protein to 
Increase the Efficacy of Endoplasmic Reticulum Stress-Induced Apoptosis for Melanoma Therapy. J 
Invest Dermatol 130:2250-2258 
  
STATISTICAL ANALYSIS 
Data were expressed as median expression levels between groups (all P values 
presented are unadjusted for multiple testing). Independent group analysis between 
naevi and melanoma, as well as localised and metastatic disease (eventual AJCC stage 
I/II versus eventual AJCC stage III/IV disease) was determined by Mann-Whitney U (a 
non-parametric equivalent of a non-paired t-test). The Kruskal-Wallis method (a non-
parametric analogue of a one-way ANOVA) was used for analysis of variance between 
AJCC cohorts. Difference between “high” and “low” p62 expression levels for survival 
curve analysis was tested using the Wilcoxon Signed Rank Test (a further non-
parametric analogue of the t-test). Univariate survival curves and subsequent Log-rank 
(Mantel-Cox) survival analysis was undertaken using R 2.15.0 (R Foundation for 
Statistical Computing). Multivariate Cox proportional hazards models (a form of survival 
analysis which explicitly takes into account the effects of possible confounders) were 
fitted with a 'forwards-backwards' iterative approach beginning with lower order terms to 
select interaction terms, using the coxph & anova functions in R 2.15.0 (R Foundation 
for Statistical Computing) and high/low  p62 expression as a stratifying variable. 
Covariates considered were: age, sex, dichotomized Breslow depth (<2mm), ulceration 
status, stage at diagnosis and mutation status. A P value <0.05 was considered 
significant throughout. 
Interactions higher than second order were not considered since no second order 
interaction term was found to provide a significant improvement the baseline model.  
The final model obtained for the multivariate time to metastasis analysis was: 
Surv ~ sex + breslow.group  + mutation + strata(p62) 
 
 
 . 
 
 
Table S1: Demographic data of study cohort patient samples 
 
Patient Demographics 
Melanoma 
Number of patients 121 
Male: Female 62:59 
Median age at diagnosis (range) 56 (1-87) 
AJCC Stage at diagnosis  
     I 67 
     II 54 
Eventual AJCC Stage  
     I 57 
     II 23 
     III/IV 41 
NRAS/BRAF Mutational status  
     NRAS mutant               19 
     BRAF mutant 48 
     Wild-type 54 
Melanoma subtype  
     Superficial Spreading 97 
     Nodular 24 
Median Breslow Depth (range) 1.6 mm (0.3-19) 
Median Clark’s Level (range) III (II-V) 
Number of Ulcerated Primary Tumours 29 (24%) 
Number of melanoma related deaths  25 (21%) 
Melanocytic Naevi 
Number of patients 29 
Male:Female 12:17 
Median age at diagnosis (range)                      36 (11-79) 
Subtype  
     Compound 5 
     Intradermal 24 
 Site  
     Head and neck 12 
     Trunk 11 
     Limbs 6 
 
 
 
 
  
Table S2. Univariate analysis of hypothesised risk factors for Disease Free Survival 
and Melanoma Specific Mortality using Log-rank (Mantel-Cox) calculations. Analysed 
values for Breslow depth and age were determined using median values for each 
variable within the study cohort. 
 
Univariate Analysis Disease Free Survival 
Variable Hazard Ratio 
95% Confidence 
Interval 
P value 
p62 expression 
<20% 
1.66 1.03 to 2.69 0.03 
Breslow depth 
>1.6mm 
4.43 2.28 to 8.62 <0.0001 
Ulcerated primary 
tumour 
2.34 1.49 to 3.67 <0.0001 
Male sex 1.96 1.02 to 3.77 0.04 
NRAS/BRAF mutant 1.61 1 to 2.61 0.05 
Age >56 years 1.1 0.7 to 1.74 0.67 
Univariate Analysis for Melanoma Specific Mortality 
p62 expression 
<20% 
1.5 0.83 to 2.74 0.18 
Breslow depth 
>1.6mm 
3.45 1.61 to 7.39 <0.0001 
Ulcerated primary 
tumour 
1.9 1.06 to 3.43 0.03 
Male sex 3.26 1.29 to 8.22 0.01 
NRAS/BRAF 
mutant 
1.28 0.72 to 2.31 0.4 
Age >56 years 1.2 0.66 to 2.18 0.54 
 
 
 
 
 . 
 
 
Table S3: Multivariate analysis of hypothesised risk factors for Disease Free Survival 
using Cox Proportional Hazards model.  
 
 
 
 
 
 
 
 
 
 
Multivariate Analysis Disease Free Survival 
Variable Hazard Ratio 
95% Confidence 
Interval 
P value 
Male Sex 2.001 0.9968-4.015 0.05 
Breslow depth >= 
2mm 
3.361 1.9625-5.755 1E-5 
NRAS/BRAF Mutant 1.4797 0.7034-3.113 0.30 


